Skip to main content
Javier Molina-Cerrillo on Muck Rack

Javier Molina-Cerrillo

As seen in: Nature, Wiley Online Library, The Oncologist, MDPI, European Urology, Cancer Treatment Reviews
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Javier

Contact Javier, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Microplastics as both a driver of genitourinary cancers and a deliverer of treatments

|
By Kannan Sridharan, Brigida Anna Maiorano, Farah Rehan, Francesca Maradonna, ELISABETTA Giorgini, Tarek Taha, Javier Molina-Cerrillo, Sebastiano Buti, Francesco Piva, Francesco Massari, Matteo Santoni
| Nature Verified
Abstract Microplastics and nanoplastics (MNPs) are environmental contaminants increasingly detected in human tissues, raising public health concerns. Although evidence is still insufficient to directly link MNPs to genitourinary cancers (GU), this Review examines their potential role in prostate, bladder, and renal cell carcinoma. Proposed mechanisms include chronic inflammation, oxidative stress, genotoxicity, and endocrine disruption driven by plastic-associated additives.
Open in Who Shared Issue with article?

Re: Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer

|
By Javier Molina-Cerrillo, Teresa Alonso-Gordoa
| European Urology Verified
Get full text access Log in, subscribe or purchase for full access. References 1. Srinivasan, R. ∙ Gurram, S. ∙ Singer, E.A. ... Bevacizumab and erlotinib in hereditary and sporadic papillary kidney cancer N Engl J Med. 2025; 392:2346-2356 2. Pierro, M.J. ∙ Gallan, A. ∙ Kilari, D. Non-clear cell renal cell carcinoma narrative review: where we are in 2024 Transl Cancer Res. 2024; 13:6403-6412 3. Fitzgerald, K.N. ∙ Lee, C.H. ∙ Voss, M.H. ...
Open in Who Shared Issue with article?

Toxicity‐related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune‐based combinations (ARON‐1 study)

|
By Javier Molina-Cerrillo, Giandomenico Roviello, María T. Bourlon, Universidad Panamericana
| Wiley Online Library Verified
CONFLICT OF INTEREST STATEMENT Javier Molina-Cerrillo declares consultant, advisory or speaker roles for IPSEN, Roche, Pfizer, Sanofi, Janssen, and BMS. Javier Molina-Cerrillo has received research grants from Pfizer, IPSEN and Roche. Francesco Massari has received research support and/or honoraria from Advanced Accelerator Applications, Astellas, Astra Zeneca, Bayer, BMS, Janssen, Ipsen, MSD, Pfizer outside the submitted work.
Open in Who Shared Issue with article?
See all 6 articles